This CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearPreferredregimen forHR+ diseasefor frail/elderlypatientsThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseDuration of timepatients willtakeabemaciclib inearly stagedisease1%This should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab This treatmentmodality isalwayscombined withlumpectomysurgeryThis drugclass are thebackbone ofHR+ diseaseThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerPatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis agentshould beinitiated withneratinib for thefirst 8 weeksBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score The ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabPreferredfrequencyof GnRHagonistsBased onOncotype DX,a score of 35will receivethis treatmentThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression This subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate The onlysteroidalaromataseinhibitor in itsdrug classThis agent cancauseendometrialcancer, but hasbone densityprotective effectThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialPatients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearPreferredregimen forHR+ diseasefor frail/elderlypatientsThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseDuration of timepatients willtakeabemaciclib inearly stagedisease1%This should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab This treatmentmodality isalwayscombined withlumpectomysurgeryThis drugclass are thebackbone ofHR+ diseaseThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerPatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis agentshould beinitiated withneratinib for thefirst 8 weeksBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score The ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabPreferredfrequencyof GnRHagonistsBased onOncotype DX,a score of 35will receivethis treatmentThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression This subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate The onlysteroidalaromataseinhibitor in itsdrug classThis agent cancauseendometrialcancer, but hasbone densityprotective effectThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialPatients withHER2+ diseasecontinuetargetedtherapy for thisduration

BC questions - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer
  2. I can give this agent in high risk BRCA 1/2 mutation for 1 year
  3. Preferred regimen for HR+ disease for frail/elderly patients
  4. This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose
  5. Duration of time patients will take abemaciclib in early stage disease
  6. 1%
  7. This should be monitored routinely every 3-4 months while receiving trastuzumab
  8. This treatment modality is always combined with lumpectomy surgery
  9. This drug class are the backbone of HR+ disease
  10. This agent is well studied for tamoxifen induced hot flashes in breast cancer
  11. Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy
  12. This agent should be initiated with neratinib for the first 8 weeks
  13. Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score
  14. The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy
  15. This agent can be added to LN+ HER2+ disease given with trastuzumab
  16. Preferred frequency of GnRH agonists
  17. Based on Oncotype DX, a score of 35 will receive this treatment
  18. This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression
  19. This subtype of breast cancer has the lowest relative 5-year survival rate
  20. The only steroidal aromatase inhibitor in its drug class
  21. This agent can cause endometrial cancer, but has bone density protective effect
  22. This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial
  23. Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial
  24. Patients with HER2+ disease continue targeted therapy for this duration